RheumaTrace™
Fast-track your rheumatology drug development with the RheumaTrace™ biomarker panel.
Introducing Nordic RheumaTrace™: a breakthrough biomarker panel for rheumatic diseases. Backed by three decades of research and over 200 peer-reviewed publications, this panel features seven carefully selected biomarkers.
These biomarkers delve into the complexities of connective tissue degradation and immune cell dynamics, providing invaluable insights for researchers and drug developers. By pinpointing the disease pathway and determining the optimal dosage for positive outcomes, our panel is at the forefront of precision medicine in rheumatology.
The RheumaTrace™ biomarker panel for rheumatological diseases (RMDs) has been developed based on 3 decades of research and more than 200 peer-reviewed publications. The panel comprises seven distinct biomarkers, carefully selected to encompass the intricacies of connective tissue degradation and immune cell dynamics. Together, these biomarkers offer researchers and drug developers invaluable insights into disease activity, the trajectory of disease progression, and the efficacy of therapeutic interventions.
By accurately identifying the critical pathway of the disease and the optimal dosage required to elicit a positive response, our panel represents a cutting-edge solution for precision medicine in rheumatology. Elevate your research with RheumaTrace™ today! |
The biomarkers in RheumaTrace™ are directly linked to the critical path of the disease and respond rapidly - within days and weeks - to effective drug intervention. With a dose-dependent effect, the panel demonstrates that only efficacious doses of the drug reach clinically significant suppression, ultimately translating into a positive drug response. As such, our panel has proven to be a valuable tool for dose-finding and efficacy prediction in phase I/II interventional trials, as well as insight into mode-of-mechanism in phase II/III. The panel is likewise suitable for assessing and comparing drug response in head-to-head studies. |  RheumaTrace™ shows pharmacodynamics and MoA |
 RheumaTrace™ enables targeted patient identification | As a smart translational medicine tool, RheumaTrace™ provides valuable support for drug (re)positioning efforts. By including connective tissue destruction markers, which have been shown to be elevated in various inflammatory and autoimmune conditions, the panel enables targeted patient identification for drug trials and therapy. Conversely, the absence of such markers in non-inflammatory conditions further enhances the panel's specificity. With the ability to accurately identify patient populations likely to respond to specific drugs, our panel represents a cutting-edge solution for personalized medicine in rheumatology. |
|
|
|
|
Research questions answered by the RheumaTrace™ biomarkers
What impact does the compound have on bone inflammation and connective tissue degradation as indicated by C1M levels? How does the compound influence inflammation and destruction of soft tissues, such as the synovium, as reflected by C3M measurements? What effects does the compound have on the disruption of epithelial and endothelial tissues, as indicated by C4M levels? Does the compound exhibit protective effects against cartilage loss and joint space narrowing, thus preserving joint integrity, reflected by C2M? To what extent does the compound affect macrophage activity as indicated by VICM levels? How does the compound influence T-cell activity, as reflected by C4G measurements? What impact does the compound have on neutrophil activity as indicated by CPa9-HNE levels? Further questions about RheumaTrace™? Get in touch with us! |
Search and find publications that we have published.
Please don't hesitate to contact us if you have any questions or other inquiries.
